All News

AI may open pathways to locate pancreatic cancer earlier and in higher-risk patient subgroups, according to Debiao Li, PhD, and Stephen Pandol, MD.

NFKB1 rs230511 genetic variant improves treatment outcomes for patients with polycythemia vera and essential thrombocythemia.

Phase 3 data support tafasitamab plus lenalidomide/rituximab as a potential new standard of care in patients with relapsed/refractory follicular lymphoma.

An artificial intelligence model may help move patients into treatment pathways for pancreatic cancer quicker, says Russell C. Langan, MD, FACS, FSSO.

Autologous transplant did not confer significantly improved overall survival regardless of induction intensity in a phase 3 trial.

Pirtobrutinib sustained BTK inhibition and improved progression-free survival in patients with CLL and SLL, data from the phase 3 BRUIN CLL-321 trial showed.

Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.

Long-term ORR, DOR, PFS, and OS data from the phase 2 Zuma-5 trial supports the use of axi-cel use in relapsed/refractory indolent Non-Hodgkin lymphoma treatment.

Lisaftoclax with pomalidomide and dexamethasone elicited positive efficacy and safety outcomes in relapsed/refractory multiple myeloma.

Regardless of high-risk features, brexucabtagene autoleucel demonstrated positive and durable responses in BTK-naive MCL.

Phase 2 results showed high undetectable MRD rates with pirtobrutinib, venetoclax, and obinutuzumab for patients with chronic lymphocytic leukemia.

Glofitamab with polatuzumab vedotin benefited patients with high-grade B-cell lymphomas and who failed prior CAR T-cell therapy.

Phase 2 data support epcoritamab monotherapy as a promising chemotherapy-free option for older patients with newly diagnosed LBCL.

Findings from the phase 1/2 CaDAnCe-101 trial showed that promising ORRs in R/R WM and R/R CLL/SLL stemmed from BGB-16673 treatment.

In patients with lens-refractory multiple myeloma, cilta-cel generated deeper minimal residual disease rates across all patient subgroups.

Pelabresib and ruxolitinib combination maintains consistent reduction of symptoms and anemia in patients with myelofibrosis.

For patients with CLL and SLL, sonrotoclax with zanubrutinib yielded high rates of overall response in the phase 1/1b BGB-11417-101 study.

In patients with VEXAS Syndrome with or without MDS, ESAs/luspatercept generated positive hematologic improvement-erythroid responses.

A panel of cancer survivorship experts outline major areas of focus and care models for improving outcomes among pediatric and adult survivors of cancer.

Patients with newly diagnosed multiple myeloma experienced sustained MRD negativity with isatuximab/bortezomib/lenalidomide/dexamethasone.

Findings from DREAMM-7 support belantamab mafodotin plus bortezomib and dexamethasone as a standard of care in relapsed/refractory multiple myeloma.

Samatha Shenoy, NP, MSN, highlighted lifestyle recommendations to help patients who are receiving talquetamab treatment for multiple myeloma.

The 2 main pafolacianine components, a folate analog and a dye, are commonly used in other medical applications.

Atrial fibrillation occur at a smaller likelihood with second-generation BTK inhibitors vs first-generation BTK inhibitors in B-cell hematologic cancers.

Phase 3 data show meaningful benefits with uproleselan in patients with primary refractory AML and post-transplant survival.

Zanubrutinib maintained a PFS benefit at 5 years vs benadmustine and rituximab for patients with CLL/SLL.

Tisagenlecleucel shows high rates of MRD-negative status among patients with relapsed/refractory follicular lymphoma in the ELARA trial.

The venetoclax regimen improved CR/CRi rates for patients with acute myeloid leukemia and myelodysplastic syndromes.

For patients with acute lymphoblastic leukemia and mantle cell leukemia, lymphodepletion then brexu-cel show positive efficacy and safety outcomes.

Minimal tumor lysis syndrome was observed with venetoclax combined with hypomethylating agents in patients with myelodysplastic syndrome.